Oral vaccine against IPNV based on antibiotic-free resistance recombinant Lactobacillus casei expressing CK6-VP2 fusion protein

Hua, Xiaojing; Zhou, Ying; Feng, Ying; Duan, Kexin; Ren, Xuanyu; Sun, Jinhui; Gao, Shuai; Wang, Na; Li, Jiahui; Yang, Jiawei; Xia, Dong; Li, Chunyue; Guan, Xiaohong; Shi, Wen

doi:10.1016/j.aquaculture.2021.736425

Cited by 13 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dosages used in these experiments are between 10 7 to 2x10 8 CFU per fish gram, around 30 to 600 times the used dosage of MT006. This high dosage allows reduce the spleen viral load of IPNV 32 times ( 37 ), far more than our results that show a reduction of 3 -4 times, in the first days after the challenge. It remains to determine whether longer treatment with MT006 has the potential to reduce the viral load to levels similar or lowers at the observed with the immunizing Lactobacillus casei expressing the epitopes of VP2 of IPNV ( 37 ).…”

Section: Discussioncontrasting

confidence: 45%

“…There, the immune cells could stimulate other cells either by endogenous release of interferon or by the release of interferon produced by MT006, in a mechanism similar to that observed when dendritic cells interact with commensal bacteria in the mammalian intestine and transport them to the lymph nodes (89). This mechanism could explain the immunizing properties of orally administered recombinant Lactic Acid Bacteria that express epitopes from microbial pathogens of fish (33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44). The dosages used in these experiments are between 10 7 to 2x10 8 CFU per fish gram, around 30 to 600 times the used dosage of MT006.…”

Section: Discussionmentioning

confidence: 90%

“…This high dosage allows reduce the spleen viral load of IPNV 32 times (37), far more than our results that show a reduction of 3 -4 times, in the first days after the challenge. It remains to determine whether longer treatment with MT006 has the potential to reduce the viral load to levels similar or lowers at the observed with the immunizing Lactobacillus casei expressing the epitopes of VP2 of IPNV (37). The characterization of the immune response at the gut level during and after the administration of MT006 should help to clarify if this proposed mechanism plays a role in the immune stimulation produced by the Lactococcus lactis strain expressing rIFN-Ia.…”

Section: Discussionmentioning

confidence: 99%

“…The oral administration of these improved probiotics produces systemic effects, conferring protection against virus (29), bacterial pathogens (30,31), and parasites (32). In salmonids, oral administration of Lactobacillus casei species expressing IPNV epitopes has shown to confer protection against the virus (33)(34)(35)(36)(37), while Lactococcus lactis strains have been used to orally immunize against Hirame novirhabdovirus in flounder (38), Carp spring viremia in common carps (39), the protozoa Ichthyophthirius multifiliis in Goldfish (40), and against the viral hemorrhagic septicemia in rainbow trout (41). Oral administration of recombinant Lactobacillus casei expressing epitopes of Aeromona veronii confers protection against this pathogen in Cyprinus carpio (42,43), and Carassius carassius (44), while Lactobacillus plantarum expressing G protein of spring viremia of carp virus (SVCV) (45) and the ORF81 protein of koi herpesvirus (KHV) has shown confers protection against both viruses with high titers of IgM after its oral administration to Cyprinus carpio (46).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Lactococcus lactis Expressing Type I Interferon From Atlantic Salmon Enhances the Innate Antiviral Immune Response In Vivo and In Vitro

et al. 2021

View full text Add to dashboard Cite

In salmon farming, viruses are responsible for outbreaks that produce significant economic losses for which there is a lack of control tools other than vaccines. Type I interferon has been successfully used for treating some chronic viral infections in humans. However, its application in salmonids depends on the proper design of a vehicle that allows its massive administration, ideally orally. In mammals, administration of recombinant probiotics capable of expressing cytokines has shown local and systemic therapeutic effects. In this work, we evaluate the use of Lactococcus lactis as a type I Interferon expression system in Atlantic salmon, and we analyze its ability to stimulate the antiviral immune response against IPNV, in vivo and in vitro. The interferon expressed in L. lactis, even though it was located mainly in the bacterial cytoplasm, was functional, stimulating Mx and PKR expression in CHSE-214 cells, and reducing the IPNV viral load in SHK-1 cells. In vivo, the oral administration of this L. lactis producer of Interferon I increases Mx and PKR expression, mainly in the spleen, and to a lesser extent, in the head kidney. The oral administration of this strain also reduces the IPNV viral load in Atlantic salmon specimens challenged with this pathogen. Our results show that oral administration of L. lactis producing Interferon I induces systemic effects in Atlantic salmon, allowing to stimulate the antiviral immune response. This probiotic could have effects against a wide variety of viruses that infect Atlantic salmon and also be effective in other salmonids due to the high identity among their type I interferons.

show abstract

Section: Discussioncontrasting

confidence: 45%

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lactococcus lactis Expressing Type I Interferon From Atlantic Salmon Enhances the Innate Antiviral Immune Response In Vivo and In Vitro

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A novel bivalent DNA vaccine developed against IPNV that resulted in inducing significant immune responses in rainbow trout has been reported (Xu et al 2017 ). A recently conducted study on oral vaccines against IPNV reported that genetically engineered recombinant Lactobacillus casei provided promising protection in salmonids (Hua et al 2021 ).…”

Section: Current Status Of Fish Vaccines and Its Applications-mentioning

confidence: 99%

A review on the recent advances and application of vaccines against fish pathogens in aquaculture

2022

View full text Add to dashboard Cite

Globally, aquaculture has faced serious economic problems due to bacterial, viral, and various other infectious diseases of different origins. Even though such diseases are being detected and simultaneously treated with several therapeutic and prophylactic methods, the broad-spectrum activity of vaccines plays a vital role as a preventive measure in aquaculture. However, treatments like use of antibiotics and probiotics seem to be less effective when new mutant strains develop and disease causing pathogens become resistant to commonly used antibiotics. Therefore, vaccines developed by using recent advanced molecular techniques can be considered as an effective way of treating disease causing pathogens in aquatic organisms. The present review emphasizes on the current advances in technology and future outlook with reference to different types of vaccines used in the aquaculture industries. Beginning with traditional killed/inactivated and live attenuated vaccines, this work culminates in the review of modern new generation ones including recombinant, synthetic peptides, mucosal and DNA, subunit, nanoparticle-based and plant-based edible vaccines, reverse vaccinology, and monovalent and polyvalent vaccines.

show abstract

Oral Lactobacillus casei expressing VP56310–500 and adjuvant flagellin C delivered by alginate-chitosan microcapsules remarkably enhances the immune protection against GCRV infection in grass carp

et al. 2023

View full text Add to dashboard Cite

Oral vaccine against IPNV based on antibiotic-free resistance recombinant Lactobacillus casei expressing CK6-VP2 fusion protein

Cited by 13 publications

References 48 publications

Lactococcus lactis Expressing Type I Interferon From Atlantic Salmon Enhances the Innate Antiviral Immune Response In Vivo and In Vitro

Lactococcus lactis Expressing Type I Interferon From Atlantic Salmon Enhances the Innate Antiviral Immune Response In Vivo and In Vitro

A review on the recent advances and application of vaccines against fish pathogens in aquaculture

Oral Lactobacillus casei expressing VP56310–500 and adjuvant flagellin C delivered by alginate-chitosan microcapsules remarkably enhances the immune protection against GCRV infection in grass carp

Contact Info

Product

Resources

About